Valuation : Pelthos Therapeutics Inc.

Market Cap 95.71M 82.47M 77.33M 70.59M 133M 9.15B 133M 917M 358M 4.62B 359M 352M 15.31B P/E 2026 *
-1.46x
P/E 2027 * -8.89x
Enterprise Value 95.71M 82.47M 77.33M 70.59M 133M 9.15B 133M 917M 358M 4.62B 359M 352M 15.31B EV / Sales 2026 *
1.5x
EV / Sales 2027 * 0.85x
Free-Float
50.69%
Yield 2026 *
-
Yield 2027 * -
1 day-1.04%
1 week-3.37%
Current month-13.99%
1 month-11.24%
3 months-4.46%
6 months+2.03%
Current year-20.48%
1 week 24
Extreme 24
28.17
1 month 24
Extreme 24
29.8
Current year 18.19
Extreme 18.19
30.99
1 year 18.19
Extreme 18.19
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap.
2/7/26 Sell

Director

-558 0.0161%
2/7/26 Sell

Director

-786 0.0226%
2/7/26 Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
-1.04%-3.37%+7.22% - 95.71M
-0.70%-7.07%+59.39%+110.62% 1,048B
-0.02%-1.85%+51.17%+61.44% 640B
-0.82%-3.42%+23.07%+73.57% 456B
-1.46%-4.50%+37.43%+38.41% 362B
-0.72%-2.89%+21.86%+36.79% 295B
-1.19%-2.21%+1.35%+10.79% 255B
-1.27%-1.63%+51.31%+68.45% 236B
+0.08%-1.78%-17.64%-54.29% 204B
-2.43%-0.64%+28.99%+88.46% 185B
Average -0.92%-1.27%+26.42%+48.25% 368.17B
Weighted average by Cap. -0.75%-1.92%+37.97%+64.60%

Financials

2026 *2027 *
Net sales 63.75M 54.93M 51.5M 47.02M 88.57M 6.09B 88.85M 611M 238M 3.08B 239M 234M 10.2B 112M 96.7M 90.66M 82.76M 156M 10.73B 156M 1.08B 420M 5.41B 421M 412M 17.95B
Net income -62.08M -53.5M -50.16M -45.79M -86.25M -5.93B -86.53M -595M -232M -3B -233M -228M -9.93B -24.96M -21.5M -20.16M -18.41M -34.67M -2.39B -34.78M -239M -93.33M -1.2B -93.7M -91.66M -3.99B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
29/08/26 US$24.65 -1.40% 34,178
27/08/26 US$25.00 -6.65% 83,493
26/08/26 US$26.78 -1.54% 36,434
25/08/26 US$27.20 +2.18% 50,927
24/08/26 US$26.62 +4.35% 151,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
25.00USD
Average target price
53.14USD
Spread / Average Target
+112.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock